Company Overview of H. Lee Moffitt Cancer Center & Research Institute
H. Lee Moffitt Cancer Center & Research Institute is a not for-profit institution that focuses on prevention and cure of cancer. The institution offers private patient rooms, blood and marrow transplant programs, outpatient treatment programs, patient care, research, and education services. Additionally, it publishes Today's Tomorrows, a community newsletter about cancer care, research, and education. H. Lee Moffitt was founded in 1986 and is based in Tampa, Florida.
10441 University Center Drive
Tampa, FL 33612
Founded in 1986
Key Executives for H. Lee Moffitt Cancer Center & Research Institute
Chief Executive Officer and Center Director
Executive Vice President Applied Science
Vice President of Public Relations and Marketing
Compensation as of Fiscal Year 2015.
H. Lee Moffitt Cancer Center & Research Institute Key Developments
Bristol-Myers Squibb Co. Partners with Moffitt Cancer Center to Advance Immuno-Oncology Research
Sep 25 15
Bristol-Myers Squibb Co. partnered with Moffitt Cancer Center to advance immuno-oncology research as part of Bristol-Myers' Immuno-Oncology Rare Population Malignancy (I-O RPM) program. Bristol-Myers and Moffitt will conduct various early phase clinical studies. The partnership will foster new Moffitt investigator-initiated studies for rare tumors and gives the faculty opportunity to educate research students about innovative clinical trials.
Signal Genetics, Inc. and Moffitt Cancer Center Enter into Research Agreement in Multiple Myeloma
Sep 8 15
Signal Genetics, Inc. announced that the company has entered into an agreement with Moffitt Cancer Center to further validate the clinical utility of its MyPRS test in multiple myeloma and its precursor conditions, smoldering multiple myeloma and MGUS (collectively asymptomatic monoclonal gammopathies, or AMG). Signal plans three validation studies with multiple Moffitt investigators, including: Kenneth M. Shain, M.D., Scientific Director of the Moffitt Myeloma Working Group, Melissa Alsina, M.D., Multiple Myeloma Transplant Program Leader, Rachid Baz, M.D., Associate Member of the Malignant Hematology Program and Taiga Nishihori, M.D., Assistant Member of the Blood & Marrow Transplantation Program. Under the agreement, Signal will perform MyPRS testing on patient specimens to better inform key patient management decisions, including the risk of progression from the constellation of AMG disorders to symptomatic multiple myeloma. The parties anticipate starting work in 2015. As the data is collected, Signal and Moffitt anticipate presenting their findings at scientific conferences and publishing in high impact medical journals.
Cancer Genetics, Inc. Enters into Multi-Year Research Collaboration with Moffitt Cancer Center for Genomics-Based Prediction of Side Effects Associated with Chemotherapy
May 6 15
Cancer Genetics, Inc. announced that it has entered into a series of collaborative studies with leading researchers at Moffitt Cancer Center in Tampa, Florida. The studies, led by Moffitt researchers Heather Jim, PhD, Diane Portman, MD, Howard McLeod, PharmD, and Gillian Bell, PharmD will examine a number of genetic variants as predictors for the most common side effects associated with chemotherapy treatment. Chemotherapy-induced nausea and vomiting (CINV) is a significant clinical challenge experienced by over 50% of patients receiving chemotherapy, even when general-purpose prophylactic anti-emetic therapies are prescribed according to clinical guidelines. The first of these collaborative studies will seek to validate and improve existing risk prediction indices of acute and delayed CINV in patients undergoing chemotherapy. This prospective study will determine whether the inclusion of variations in genes involved in the metabolism of anti-emetic drugs improves the ability to accurately predict which patients are more likely to experience side effects from chemotherapy regimens. Tailored anti-emetic treatment in patients at risk of CINV has the potential to significantly reduce incidence, while decreasing CINV-related medical visit costs, which average $40,001 per patient. A second collaboration will examine the role of individual genetic variants in the effectiveness of pain control in cancer. Pain is one of the most difficult symptoms associated with cancer and its treatment. Opioid and non-opioid analgesics and co-analgesics are frequently used to improve pain control, but patients vary considerably in their response to these drugs. This study will include Moffitt cancer patients treated in the outpatient setting and will seek to identify genetic associations for patient-reported pain outcomes.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|